Another reason to ‘pull it out as soon as is safe and reasonable’
Use of asthma meds were linked to abdominal aortic aneurysm
One-third of Medicare patients died in the 2 years after the procedure.
I found this article quite helpful in my own decision regarding whether or not to continue my daily aspirin 81 mg dose.
The bump I gave myself on the shin a few weeks ago that bled profusely and took hours to clot was also quite helpful in my decision regarding whether or not to continue my daily aspirin 81 mg dose.
Check out the following link. If you’re an older male you might find this of interest.
This link takes you to the 2012 Circulation article.
More links for your reading and research pleasure.
Researchers from Professor Kausik Ray’s group at St George’s, University of London investigated the drug’s effectiveness in primary prevention and the prevalence of side effects. They also assessed if aspirin had any impact on the risk of death from cancer among people considered at risk of cardiovascular disease.
They analysed data from nine clinical trials involving over 100,000 participants without a history of cardiovascular disease. Half of the participants took aspirin and half took a placebo. The average participant in the aspirin arm of these trials took aspirin for about six years.
The researchers found that although aspirin in conventional daily or alternate day doses reduced the risk of total cardiovascular disease events by 10 per cent, this was largely due to a reduction in non-fatal heart attacks. It did not include a reduction in other cardiovascular disease events including death from heart attack, or fatal or non-fatal stroke.
The study also showed that this benefit was almost entirely offset by a 30 per cent increase in risk of life-threatening or debilitating internal bleeding events. This means that while one cardiovascular disease event was averted for every 120 people treated with aspirin for about six years, one in 73 people suffered from potentially significant bleeding during the same period.
High HbA1c levels were associated with increased risk for all-cause mortality and death from CVD, coronary heart disease, and cerebral infarction in general East Asian populations, as in Western populations.
More than a quarter of a billion people in the world have peripheral artery disease (PAD), with poorer countries disproportionately affected, the first global analysis of the disease found.
The global prevalence of PAD increased by 24% from 2000 to 2010, from 164 million to 202 million, according to Gerald Fowkes, BSc, MBChB, from the Centre for Population Health Sciences at the University of Edinburgh in Scotland, and colleagues.